Fulfilling our commitment to employees and mission to patients in the context of the COVID-19 pandemic

As the COVID-19 pandemic reaches a critical stage in several countries around the world, we at Ipsen remain firm in our commitments to our employees, our communities and patients. Our top priorities are and will remain to ensure the safety of Ipsen’s employees around the world and to focus on business continuity so that we can provide patients with access to our medicines.

Firstly, to ensure health and safety of our employees, we are complying with local health authorities in all of our locations. The Ipsen leadership team is working together closely to give clear directives to all of our collaborators, in line with the most up-to-date recommendations in each location, with many sites shifting to telecommuting.

Secondly, we are working to ensure business continuity at our manufacturing sites, which will continue to operate, so that we can maintain the production and distribution of our medicines for every market we are present in. Our manufacturing sites share one essential objective: ensuring access to our medicines for patients. We are working closely with our national and international suppliers to monitor the provision of goods and services, with the goal of continuing our operations as seamlessly as possible. At this time, we do not anticipate any supply shortage.

Finally, as a Group, we would like to recognize our incredible teams around the world who, despite the difficulties of the last days and weeks, continue to demonstrate their commitment to patients with agility, determination and calm.

If you are a patient and have questions about your Ipsen medication, please contact your physician or you may also contact our Medical Information teams: https://www.ipsenmedicalinformation.com/

©2022 Ipsen Biopharmaceuticals, Inc. MP-US-000472 June 2022